MC-Sq-Cit-PAB-Dolastatin10 |
| Catalog No.GC36563 |
MC-Sq-Cit-PAB-Dolastatine10 est un conjugué médicament-lieur pour ADC avec une activité antitumorale puissante en utilisant Dolastatine10 (un inhibiteur de polymérisation de la tubuline), lié via le lieur ADC MC-Sq-Cit-PAB.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1941168-65-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MC-Sq-Cit-PAB-Dolastatin10 has a bioreversible linkage based on a quaternary ammonium for targeted delivery and it can improve pharmacokinetics and the therapeutic index. MC-Sq-Cit-PAB-Dolastatin10 is used for the antibody-drug conjugates (ADC) to treat various diseases or disorders, e.g. characterized by the overexpression of a tumor antigen[1,2].
ADC1-2 (anti-CD22 10F4v3 LC K149C MC-Sq-Cit-PAB-Dolastatin 10) displays target-specific killing in WSU-DLCL2 human diffuse large B-cell lymphoma tumors with IC50 of 0.385 nM, and ADC1-1 (anti-Napi2b 10H1 11.4B LC K149C MC-Sq-Cit-PAB-Dolastatin 10) displays target-specific killing in human ovarian cancer IGROV-1 and OVCAR-3x2.1 with IC50s of 3.19 nM, 1.52 nM, respectively[1].
[1]. FLYGARE, John A, et al. Quaternary amine compounds and antibody-drug conjugates thereof. WO2016090050A1. [2]. Staben LR, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nat Chem. 2016 Dec;8(12):1112-1119.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *